Dosimetric predictors of diarrhea during radiotherapy for prostate cancer.
OBJECTIVE
To investigate dosimetric predictors of diarrhea during radiotherapy (RT) for prostate cancer.


METHODS
All patients who underwent external-beam radiotherapy as part of treatment for localized prostate cancer at the University of Texas Medical Branch, Galveston, TX, USA, from May 2002 to November 2006 were extracted from the own database. From the cumulative dose-volume histogram (DVH), the absolute volumes (V-value) of intestinal cavity (IC) receiving 15, 30, and 45 Gy were extracted for each patient. Acute gastrointestinal toxicity was prospectively scored at each weekly treatment visit according to CTC (Common Toxicity Criteria) v2.0. The endpoint was the development of peak grade >or= 2 diarrhea during RT. Various patient, tumor, and treatment characteristics were evaluated using logistic regression.


RESULTS
149 patients were included in the analysis, 112 (75.2%) treated with whole-pelvis intensity-modulated radiotherapy (WP-IMRT) and 37 (24.8%) with prostate-only RT, including or not including, the seminal vesicles (PORT +/- SV). 45 patients (30.2%) developed peak grade >or= 2 diarrhea during treatment. At univariate analysis, IC-V(15) and IC-V(30), but not IC-V(45), were correlated to the endpoint; at multivariate analysis, only IC-V(15) (p = 0.047) along with peak acute proctitis (p = 0.041) was independently correlated with the endpoint.


CONCLUSIONS
These data provide a novel and prostate treatment-specific "upper limit" DVH for IC.
Sanguineti
Giuseppe
G
Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA. gsangui1@jhmi.edu
Endres
Eugene J
EJ
Sormani
Maria Pia
MP
Parker
Brent C
BC
D000368:Aged; D015897:Comorbidity; D003967:Diarrhea / Q000175:diagnosis / Q000453:epidemiology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015994:Incidence; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000175:diagnosis / Q000453:epidemiology*; D011879:Radiotherapy Dosage; D012062:Relative Biological Effectiveness; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013781:Texas / Q000453:epidemiology; D016896:Treatment Outcome